載入中
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
前收盤價
US$19.78
+US$0.20 · +1.02%
盤前
US$19.68
−US$0.10 · -0.51%
10月12日 上午7:47 ET
盤中時間採用ET。市場資料可能有所延遲。
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
日內區間
目前US$19.78
52週區間
目前US$19.78
盤中時間採用ET。市場資料可能有所延遲。
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
日內區間
目前US$19.78
52週區間
目前US$19.78
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 10.72億 USD | 9.58億 USD | 7.26億 USD | 5.17億 USD | 4.84億 USD |
| 銷貨成本 | 8899.8萬 USD | 8184.1萬 USD | 4573.1萬 USD | 1016.6萬 USD | 1914.1萬 USD |
| 毛利 | 9.83億 USD | 8.76億 USD | 6.81億 USD | 5.07億 USD | 4.65億 USD |
| 研究與開發 | 3.29億 USD | 3.03億 USD | 3.52億 USD | 3.62億 USD | 2.39億 USD |
| 銷售、一般及管理費用 | 5.49億 USD | 4.88億 USD | 4.02億 USD | 3.69億 USD | 3.96億 USD |
| 營業費用 | 8.78億 USD | 6.45億 USD | 7.54億 USD | 7.31億 USD | 6.35億 USD |
| 利息收入 | 3172.2萬 USD | 2545.8萬 USD | 1723.4萬 USD | 661萬 USD | 59.1萬 USD |
| 折舊和攤銷 | 1176萬 USD | 1588.3萬 USD | 555.2萬 USD | 202.6萬 USD | 334.4萬 USD |
| 營業利益 | 1.05億 USD | 2.31億 USD | −7337.9萬 USD | −2.24億 USD | −1.7億 USD |
| 淨利 | 3.91億 USD | 2.26億 USD | −6128.6萬 USD | −2.16億 USD | −1.68億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
